Table 1.
Socio-demographic and clinical characteristics of the study population (N = 971).
Variable | N (%) |
---|---|
Age (years) | |
<50 | 172 (17.7%) |
50–60 | 397 (40.9%) |
>60 | 402 (41.4%) |
Gender | |
Male | 452 (46.5%) |
Female | 519 (53.5%) |
BMI (kg/m 2 ) | |
Normal: <25 | 72 (7.4%) |
Overweight: 25–29.9 | 297 (30.6%) |
Obese: ≥30 | 602 (62.0%) |
Waist circumference (cm) | |
(M < 94, F < 80) | 88 (9.1%) |
(M ≥ 94, F ≥ 80) | 883 (90.9%) |
Marital status | |
Married | 826 (85.1%) |
Single | 32 (3.3%) |
Divorced/ widow | 113 (11.6%) |
Occupational status | |
Employed | 236 (24.3%) |
Not employed | 735 (75.7%) |
Monthly income (JD) | |
< 300 | 294 (30.3%) |
301–500 | 344 (35.4%) |
>500 | 333 (34.3%) |
Diabetes duration (years) | |
>10 | 462 (47.6%) |
≤ 10 | 509 (52.4%) |
Diabetes treatment | |
Oral Hypoglycemic agents (OHA) | 501 (51.6) |
Insulin only | 30 (3.1%) |
Insulin + OHA | 440 (45.3%) |
Statin duration (years) | |
>5 | 420 (53.5%) |
≤ 5 | 365(46.5%) |
Smoking | |
Yes | 266 (27.4%) |
No | 705 (72.6 %) |
Level of education | |
High school or less | 453 (46.7%) |
More than high school | 518 (53.3%) |
Received anti-dyslipidemia agent | 882 (84.7%) |
Statins | 782 (80.5%) |
Fibrates | 104 (10.7%) |
Statin-fibrate combination | 92 (9.5%) |
Ezetimibe | 2 (0.2%) |
Omega-3 | 172 (17.7%) |
Comorbidities | |
Hypertension | 662 (68.2%) |
Ischemic heart disease | 182 (18.7%) |
Hypothyroidism | 127 (13.1%) |
At least one comorbidity | 729 (75.1%) |
Diabetes complications | |
Retinopathy | 234 (24.1%) |
Neuropathy | 266 (27.4%) |
Nephropathy | 147 (15.1%) |
At least one complication | 458 (47.2%) |